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Abstract
Malignant peripheral nerve sheath tumours (MPNST) are aggressive sarcomas that develop in about 10% of patients with
the genetic disease neurofibromatosis type 1 (NF1). Molecular alterations contributing to MPNST formation have only
partially been resolved. Here we examined the role of Pten, a key regulator of the Pi3k/Akt/mTOR pathway, in human
MPNST and benign neurofibromas. Immunohistochemistry showed that Pten expression was significantly lower in MPNST
(n = 16) than in neurofibromas (n = 16) and normal nervous tissue. To elucidate potential mechanisms for Pten down-
regulation or Akt/mTOR activation in MPNST we performed further experiments. Mutation analysis revealed absence of
somatic mutations in PTEN (n = 31) and PIK3CA (n = 38). However, we found frequent PTEN promotor methylation in primary
MPNST (11/26) and MPNST cell lines (7/8) but not in benign nerve sheath tumours. PTEN methylation was significantly
associated with early metastasis. Moreover, we detected an inverse correlation of Pten-regulating miR-21 and Pten protein
levels in MPNST cell lines. The examination of NF12/2 and NF1+/+Schwann cells and fibroblasts showed that Pten
expression is not regulated by NF1. To determine the significance of Pten status for treatment with the mTOR inhibitor
rapamycin we treated 5 MPNST cell lines with rapamycin. All cell lines were sensitive to rapamycin without a significant
correlation to Pten levels. When rapamycin was combined with simvastatin a synergistic anti-proliferative effect was
achieved. Taken together we show frequent loss/reduction of Pten expression in MPNST and provide evidence for the
involvement of multiple Pten regulating mechanisms.
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Introduction
Malignant peripheral nerve sheath tumours (MPNST) are
aggressive soft tissue sarcomas that develop with an incidence of
1:100.000. Although rare in the general population MPNST
develop frequently in patients with the genetic disorder neurofibro-
matosis type 1 (NF1), which occurs with an incidence of 1:3500 [1].
The life-time risk of developing MPNST is estimated to be 8–13%
[2] for NF1 patients, who account for about 50% of all MPNST.
MPNST generally arise from plexiform neurofibromas (pNF) in
NF1 patients and constitute the major cause for reduced life
expectancy with only 21% of patients surviving longer than 5 years
after diagnosis. Loss of the tumour suppressor gene (TSG) NF1 is
only a first step in tumourigenesis. During the course of malignant
progression, further alterations are acquired in TSG and oncogenes
like TP53, CDKN2A, EGFR, and PDGFRA [3,4,5,6,7]. Although
sporadic and NF1-associated MPNST share many similarities in
their molecular pathogenesis, Ras mutations are linked to sporadic
MPNST whereas PTEN monosomy segregates with NF1-associated
cases [8]. The currently dim treatment options for MPNST patients
may be improved by a better knowledge on molecular alterations,
which could lead to novel strategies of targeted therapy. Neurofi-
bromin, the NF1 gene product, is a negative regulator of the Ras
oncoprotein. Moreover, it was shown that the Akt/mTOR
(mammalian Target of Rapamycin) pathway is activated in NF1
deficient cells [9]. This pathway is attractive for targeted therapy
since different mTOR inhibitors are already approved for clinical
application. Recently we found allelic loss of PTEN (Phosphatase
and tensin homologue deleted from chromosome 10) in 58%
MPNST [7]. Pten protein is a major regulator of the Pi3k/Akt/
mTOR pathway. Loss or down-regulation of Pten expression leads
to the activation of this pathway and thus promotes malignant
progression. PTEN is the second most frequently altered TSG and
inactivated in a variety of tumour entities including glioblastoma,
prostate cancer and melanoma. Pten has lipid phosphatase activity
and dephosphorylates phosphatidylinositol-(3,4,5)-triphosphate
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(PIP3) to phosphatidylinositol-(4,5)-bisphosphate (PIP2). Thereby it
antagonizes the activity of the phosphatidylinositol-3-kinase (Pi3k)
which converts PIP2 to PIP3. Via this mechanism Pten controls the
Akt/mTor pathway, which promotes multiple functions, including
cell growth and survival, proliferation, apoptosis, invasion, migra-
tion and angiogenesis.
Recently, a transgenic mouse model provided evidence for an
important role of Pten in development of benign and malignant
nerve sheath tumours [10]. The authors demonstrated that in
addition to a constitutively active K-Ras mutant a reduced Pten
dosage was necessary for tumour formation. Deletion of both Pten
alleles was observed in malignant but not in benign nerve sheath
tumours. This study points towards a crucial role of Pten in nerve
sheath tumour formation, however, the employed mouse model
does not reflect the genetic nature of NF1 patients and the
question why mice haploinsufficient for Pten and Nf1 completely
lacked tumour development remains unsolved.
Here we determined the frequency of Pten alterations in human
MPNST and neurofibromas and examined underlying mecha-
nisms.
Materials and Methods
Tumour Tissue, DNA and RNA Extraction
Paraffin embedded and frozen tumour and nerve samples were
collected in the following German hospitals: University Hospital
Eppendorf (Hamburg), Otto-von-Guericke-University (Magde-
burg), Robert-Rössle-Hospital (Berlin), and Charité – Universi-
tätsmedizin Berlin. Following initial diagnosis in local neuropa-
thologies, all tumour samples were reviewed by the same
experienced pathologist (AvD). Tumour sections were examined
histologically prior to extraction of nucleic acids and proteins.
DNA and RNA from frozen tumours (6 MPNST and 9
neurofibromas), all cell lines and cell cultures were extracted with
Trizol reagent (Invitrogen, Karlsruhe, Germany). RNA integrity
was analysed with a Bioanalyzer from Agilent (Böblingen,
Germany). Samples with an RNA integrity number (RIN),7
were excluded. RIN of cell lines was .9. DNA extraction from
paraffin embedded material was carried out according to the
QIAamp DNA Mini Kit protocol (Qiagen, Hilden, Germany).
The investigations were carried out with the informed consent of
the patients.
Immunohistochemistry and Scoring
Immunohistochemistry on paraffin embedded slices was
performed with the BenchmarkTM system from Ventana
(Strasbourg, France). Pten antibody (A2B1, dilution 1:80) was
obtained from Santa Cruz Biotechnology (Heidelberg, Germany).
Visualization was performed with diaminobenzidine. Negative
controls without primary antibodies were carried out. Scoring was
performed according to the percentage of positive cells: ,5% was
classified as negative (2), 6–100% was classified as positive. 6–
30% of positive cells were scored with +, 31–60% with ++, .60%
with +++. A blinded repeated test produced similar results.
Immunofluorescence double staining was performed manually.
Antigen retrieval was achieved by heating. Pten (A2B1, dilution
1:80) S100 and neurofilament from DakoCytomation GmbH
(Hamburg, Germany), dilution 1:1000, antibodies were used. For
visualization we utilized 1:100 dilutions of Cy3- and Alexa Fluor
488-conjugated antibodies. Nuclei were counterstained with
DAPI. Normal skin tissue served as positive control. Slices were
photographed with the confocal laser mikroscope LSM5 Exciter
from Zeiss (Jena, Germany).
PTEN and PIK3CA Mutation Analysis
The nine coding exons of PTEN were sequenced bidirectionally
with nine primer pairs labelled either with M13-forward and –
reverse sequences conferring PCR products between 160 and
364 bp. PCR was performed in a volume of 15 ml with 20 ng of
DNA, GoTaq DNA Polymerase (Promega, Mannheim, Germany)
applying 35 cycles. Primer sequences are available on request. For
sequencing the BigDye Terminator v3.1 Sequencing Kit (Applied
Biosystems, Darmstadt, Germany) was utilized. For PIK3CA
analysis a set of five primer pairs was employed, covering exon
1, 9 and 20. The primer sets [11], PCR and single strand
confirmation polymorphism (SSCP) have been described before
[12]. For enhanced sensitivity all PCR products were separated on
8% and 14% acrylamide gels.
PTEN Promotor Methylation Analysis
Promotor methylation was done as previously described [13]
and performed by Varionostic GmbH (Ulm, Germany). Briefly,
DNA was bisulfite-treated followed by quantitative positional
methylation analysis (pyrosequencing). The methylation analysis
was restricted to CpG island 3 which contains 5 CpG sites. A
methylation of,8% of DNA was regarded as unmethylated. The
assay does not detect methylation of the PTEN pseudogene
PTENP1.
Expression Analysis by Real Time RT-PCR
Reverse transcription and DNA digestion of 1 mg RNA was
achieved with the Quantitect reverse transcription kit (Qiagen,
Hilden, Germany). Subsequent PCR reactions were performed
with Taqman Mastermix FAST and gene specific MGB probes.
PCRs were performed in triplicates in a volume of 20 ml
containing cDNA equivalents of 10 ng RNA. PCR reagents,
probes and the 7900 HT fast real time PCR system were from
Applied Biosystems (Darmstadt, Germany). Data were accepted as
valid if the standard deviation of Ct values (threshold cycles) of
triplicate reactions was ,0.5 cycles. ACTB and RPS3 were
employed as endogenous controls.
Expression of miR-21 and miR-217 was analysed with the
Taqman microRNA reverse transcription kit and subsequent
amplification with Taqman Universal PCR master mix and
Taqman microRNA assays (all from Applied Biosystems). RNU44
was used as endogenous control.
Western Blots
Subconfluent cell cultures were lysed in ice cold lysis buffer (1%
Triton X100, 100 mM NaCl, 50 mM Tris-HCl pH 7.5, 5 mM
EDTA) containing protease and phosphatase inhibitor cocktail.
For lysates of solid tumours 1–3 g of tissue was homogenized in
lysis buffer. After heat denaturation approximately 40 mg per
sample was loaded on to 12% acrylamide gels. For comparability
of different gels cell line T265 was run on every gel as an internal
standard. After blotting membranes were stained with Ponceau S
to verify protein transfer. Membranes were blocked and incubated
overnight at 4uC with primary antibodies. The p-p70S6 kinase
antibody (detects also the p-p85S6 isoform, dilution 1:2000 (R&D
Systems, Wiesbaden, Germany) and Pten antibodies (either A2B1
from Santa Cruz Biotechnology or Pten antibody from Zytomed,
both with1:200 dilutions) were used. The b-actin antibody (AC-15,
dilution 1:6.000) was from Sigma (Munich, Germany). After
washing membranes were incubated for 1 h with second
horseradish conjugated antibodies. Visualization was performed
with ECL or advanced ECL (Amersham Biosciences, Freiburg,
Germany).
PTEN in MPNST
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Cell Culture Assays
All cell lines were maintained in DMEM Glutamax-I
(1000 mg/L glucose) with 10% FCS and 5 mg/mL gentamycin
from Invitrogen (Karlsruhe, Germany). MPNST cell lines S462,
S520, 1507.2, S805 were established and provided by V. F.
Mautner, University Hospital Eppendorf, Germany [14]. MPNST
cell line STS26T was provided by G. H. De Vries (Hines VA
Hospital, Illinois, USA) [15]. MPNST cell line ST88-14 was
provided by J. DeClue (NIH, Bethesda, USA) [16]. NFS-1, low
passage culture 31002 and dermal fibroblasts have been described
elsewhere [7,17]. Mouse embryonal fibroblasts from Nf1 wildtype
and Nf12/2 mice were prepared and genotyped by D.
Kaufmann (Institute of Human Genetics, Ulm, Germany) [18].
With the exception of MPNST cells 31002 and STS26T, which
were obtained from sporadic MPNST, all other MPNST lines
were from NF1 associated MPNST. Neurofibroma derived
Schwann cells were cultured on laminin coated dishes and
cultured in DMEM supplemented with 10% FCS (Invitrogen),
2.5 mg/ml insulin (Sigma, München, Germany), 0.5 mM IBMX
(Serva, Heidelberg, Germany), and 10 nM heregulin (Peprotech,
Hamburg, Germany). 0.5 mM forskolin from Sigma was used for
normal Schwann cells (Sciencell, Carlsbad, CA) but not for
neurofibroma derived NF12/2 Schwann cells since these cells are
selectively expanded when forskolin is omitted [19]. For compar-
ative analysis Schwann cells were set to the same medium
conditions (DMEM 0.5% FCS) for at least 72 h before harvest.
When proliferation assays were performed cell lines were
maintained in DMEM containing 5% serum. 36103 cells were
seeded in 300 mL medium into 24 well plates and allowed to
adhere over night. Drugs were added in 100 mL to obtain the
indicated concentrations. Negative controls contained vehicle
only. Cell proliferation was evaluated on day 4 post-treatment
with the CellTiter 96 AQueous One Solution Cell Proliferation
Assay (Promega, Mannheim, Germany). The experiments were
performed in quadruplicate and repeated at least three times.
Rapamycin and simvastatin were purchased from Calbiochem
(Darmstadt, Germany). Fractional product concept was used to
determine whether drug combinations yielded additive or
synergistic effects.
Determination of Phospho mTOR/total mTOR and VEGF
Phosphorylated mTOR and total mTOR were simultaneously
determined with the MSD 96-well Multi-spot Phospho (Ser2448)/
total mTOR assay from Meso Scale discovery (Gaithersburg,
MD). VEGF concentration was measured in with the Multi-array
96-well plate from Meso Scale discovery. Optimal protein
concentration was between 10–20 mg in 25 ml as determined by
serial dilution. The assay was performed according to the
manufacturer’s recommendation.
Statistical Methods
SPSS version 12.0 was used for statistical analysis. Survival rates
were determined using the Kaplan–Meier method and the log
rank test. Association of parameters was assessed with Pearson
correlation and Fisher exact test. A p-value of ,0.05 was
considered as significant.
Results
Pten Expression in Nerve Sheath Tumours and Nervous
Tissue
Pten immunohistochemistry shows a significantly (p = 0.045,
Pearson correlation) reduced Pten expression in MPNST (n = 16,
3 sporadic and 13 NF1-associated MPNST) as compared to
neurofibromas (n = 16) (Figure 1a–c). Median proportion of Pten
positive cells was 30% in neurofibromas and 5% in MPNST. In
line with these data, three tumours with transition from pNF to
MPNST showed lower Pten expression in the malignant part. An
example is shown in Figure 1b, with 5% Pten positive cells in the
MPNST versus 70% positive cells in the pNF part. Figure 1c
shows Pten expression pattern in the pNF with typical spindle
shaped cell morphology. Pten staining was visible in the cytoplasm
and in the nucleus. Given that nuclear Pten has been associated
with more differentiated, resting cells we compared its subcellular
distribution in our nerve sheath tumour samples. The ratio of
nuclear Pten was higher in neurofibromas as compared to
MPNST (mean of 50% versus 30% as shown in Figure S4).
Western blot analysis shows reduced Pten expression particu-
larly in 2 of 4 MPNST (Figure 1d). However, in tumour lysates
utilized for Western blot, non-tumourous cell types like endothelial
cells contribute to Pten signals. Production of vascular endothelial
growth factor (VEGF) increases upon activation of the Akt/
mTOR pathway. Since phosphorylated proteins were difficult to
detect in lysates from primary tumours, we determined VEGF
levels and found stronger expression in MPNST than in
neurofibromas (Figure 1d).
In order to compare Pten expression levels of healthy nerve
tissue with nerve sheath tumours we examined three nerves
without diagnostic findings (Figure 2). Because all 3 samples were
highly positive we aimed to find out the exact cell type expressing
Pten in nervous tissue. Immunoflourescence double staining
revealed expression of Pten in neurofilament-positive axons as
well as in S100-positive Schwann cells (Figure 2b & c). The cross
section in Figure 2b shows nerve fibers with a central axon, double
positive for neurofilament and Pten, ensheathed by Pten positive
Schwann cells.
Next, we determined Pten expression in 9 MPNST cell lines, 4
neurofibroma derived Schwann cell cultures and dermal fibro-
blasts by western blot (Figure 3a & b). We observed that MPNST
cell lines expressed Pten at lower levels than Schwann cell cultures
or dermal fibroblasts. The only cell line with undetectable Pten
expression was NFS-1.
Pten is not Regulated by Neurofibromin
Less Pten positive cells were detected in MPNST when
compared to neurofibroma (Figure 1a). This finding parallels the
situation of neurofibromin positive cells in these tumours. To
determine if Pten might possibly be regulated by neurofibromin we
examined murine embryonal fibroblasts (MEFs) and human
Schwann cells with NF1+/+and NF12/2 status for Pten
expression. Pten protein expression was similar in NF1+/+and
NF12/2 negative cells, however, p-p70S6 kinase, an indicator for
mTOR activity, was elevated in case of NF1 deficiency (Figure 3c).
The antibody also recognizes the p85 isoform of the S6 kinase.
This isoform is, however, not activated by Akt/mTOR.
In case of MEFs we tested the impact of different culture
conditions and also determined activation of the Ras/MAPK
pathway. An increased level of p-p70S6 kinase and of p-MAPK
was detected in Nf12/2 MEFs when they were kept in DMEM
without serum or in PBS as shown in Figure S1. In a second round
of experiments we determined p-mTOR in MEFs kept in PBS for
different times. Usage of the Mesoscale system was more sensitive
and allowed better resolution than western blot. We could confirm
stronger basal mTOR activity in Nf12/2 cells (Figure S1b).
PTEN in MPNST
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Mechanisms of PTEN Regulation
Since NF1 status had no influence on Pten expression, we
proceeded with further experiments to elucidate mechanisms
responsible for Pten downregulation in MPNST.
To analyse an involvement of PTEN mutations we examined all
PTEN coding exons in 24 solid MPNST and seven MPNST cell
lines. In addition, we screened for PIK3CA sequence alterations,
since somatic mutations in this gene can also lead to Akt/mTOR
pathway activation. Activating mutations of the p110alpha subunit
of Pi3k, encoded by the PIK3CA gene, have been identified in a
broad spectrum of tumours, e.g. breast cancer and glioblastomas.
We analysed exon 1, 9 and 20, which have been identified as hot
spot regions for mutations [20] in 38 MPNST. Somatic mutations
were neither detected in PTEN nor in PIK3CA.
Next, we determined PTEN promotor methylation, a common
mechanism for Pten down-regulation. A total of 73 samples (55
solid tumours and 18 cell cultures) was analysed by quantitative
positional methylation analysis. We focused on methylation of
CpG island 3, which contains 5 CpG sides [13]. Comparison of 29
benign nerve sheath tumours (5 neurinomas, 24 neurofibromas)
and 26 solid MPNST (3 sporadic and 23 NF1-associated MPNST)
revealed a significantly higher methylation frequency in MPNST
(p = 0.001, Pearson correlation). With the exception of 3
neurofibromas, which contained 10%, 23% and 30% methylated
DNA, all other benign tumour samples were unmethylated. Five
MPNST had DNA methylation levels .50%, two between 30–
50% and four between 8–29%. Standard deviation between
individual CpG sides was generally small (,10%). Clinical data
were available for 21 MPNST patients including 3 sporadic cases
without metastasis. The tumours were grouped in two categories:
methylation ,29% (n = 14) and methylation $29% (n = 7). We
detected a significant association (log rank p = 0.015) of PTEN
methylation and appearance of metastasis (Figure S3). Pten
immunohistochemistry of the primary MPNST was available for
Figure 1. Pten expression in MPNST and neurofibroma. a)
Proportion of Pten-positive tumour cells as determined by immuno-
histochemistry. Each dot represents one tumour. Sporadic MPNST are
depicted in grey b) MPNST 29250 with a transition to pNF. Note
stronger Pten expression in the pNF (lower part). c) Higher magnifica-
tion of pNF. Original magnification 200x and 400x. d) Western blot of
MPNST and neurofibromas. VEGF concentrations in tumour lysates are
indicated.
doi:10.1371/journal.pone.0047595.g001
Figure 2. Pten expression in nerve tissue (a-c) and Schwann cell
cultures (d). a) Standard DAB staining. b) Double staining for Pten
(green) and neurofilament (red). c) Double staining for Pten (green) and
S100 (red). Original magnification 400x.
doi:10.1371/journal.pone.0047595.g002
PTEN in MPNST
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Figure 3. Western blot analysis of Pten and p-p70S6 kinase (isoform p-p70 of the S6 kinase, indicates mTOR activation) and
examination of miR-21 expression by real time PCR a) Pten analysis of MPNST cell lines, dermal fibroblasts and neurofibroma
derived Schwann cell cultures (SC1-4). The grey line indicates mean Pten expression of 4 Schwann cell cultures. b) Quantification of Pten
expression (normalized with b-actin). c) Expression of Pten and p-p70S6 kinase in NF1 positive (+/+) and NF1 negative (2/2) Schwann cells. d)
Relative expression of miR-21 as determined by real time PCR. * Endogeneous control RNU44 was not detectable. This cell line was thus omitted from
analysis. SC = neurofibroma derived Schwann cells.
doi:10.1371/journal.pone.0047595.g003
PTEN in MPNST
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only 14 tumours with clinical data and revealed no significant
correlation with metastasis. All MPNST that were analysed with
more than one method are listed in Table S1.
Moreover, we analysed 18 cell cultures comprising 9 neurofi-
broma cultures from NF1 patients, one Schwann cell culture of
nervus suralis (non-NF1 patient) and 8 MPNST cell lines. DNA
samples from cultures of benign tissues were unmethylated. In
contrast, 7 out of 8 MPNST cell lines contained methylated DNA
(median 71%, range 12–90%).
RNA of high quality was available from 6 solid MPNST, 9
neurofibromas and several cell cultures (9 MPNST cell lines;
NF12/2 Schwann cells and dermal fibroblasts). The samples
were examined by real-time PCR with a PTEN specific minor
groove–binding (MGB) probe. PTEN transcript expression did not
correlate well with PTEN promotor methylation and Pten protein
levels. Thus, we hypothesized that post transcriptional mecha-
nisms may be involved in Pten regulation. Because microRNAs
(miR) are well known regulators of Pten we determined expression
of miR-21 and miR-217. miR-21 showed an inverse correlation
(p = 0.015; Pearson correlation) with Pten protein levels in
MPNST cell lines (Figure 3d). miR-217 was not detectable in
neurofibroma derived Schwann cells and the majority of MPNST
cell lines (data not shown).
Pten Expression and Sensitivity to Rapamycin
Next, we wanted to know whether the Pten expression status of
MPNST cell lines would correlate with their sensitivity to the
mTOR inhibitor rapamycin. Using 5 MPNST cell lines and
dermal fibroblasts we observed a dose dependant inhibition of
proliferation (Figure 4a). The IC50 of rapamycin was around
10 nM for most MPNST cell lines. Highest sensitivity to
rapamycin was observed in Pten negative NFS-1 cells (,10 nM)
and lowest sensitivity was present in dermal fibroblasts
(IC50.100 nM). The correlation of Pten expression and sensitiv-
ity to rapamycin was not significant (Figure 4b; p = 0.06; Pearson
correlation).
Synergistic Effect of Rapamycin and Simvastatin
Because statins affect the activity of Ras superfamily members
and have been shown to mediate a growth inhibitory effect on
MPNST cells we evaluated whether the combination of rapamycin
and simvastatin would be synergistic. To find a simvastatin
concentration that mediates just a mild anti-proliferative effect as
single drug, we tested different concentrations of 0.1 mM, 1.0 mM,
and 10 mM. The IC50 of simvastatin on MPNST cell lines ranged
between 0.1–1.0 mM. However, a concentration of 10 mM
simvastatin was necessary to inhibit fibroblast growth by 50%.
Combined treatment approaches with low drug doses were
performed (0.1 mM simvastatin and 1.0 nM rapamycin). The
results show a synergistic effect of this drug combination in 4 of 5
cell lines (Figure S2a). Because we previously observed an
inhibitory effect of the multi-tyrosine kinase inhibitor sunitinib
on MPNST cell lines [17] we wanted to analyse sunitinib in
combination with rapamycin and simvastatin. A synergistic effect
was, however, not achieved when we combined sunitinib with
either simvastatin or rapamycin (Figure S2b & c). These
combinations actually led to an antagonistic effect in about half
of the cell lines.
Discussion
The aim of this study was to evaluate Pten alterations in human
MPNST and neurofibroma and possible consequences for
treatment with mTOR inhibitors. We demonstrate that Pten
expression in MPNST is significantly lower than in neurofibroma
indicating that its down-regulation could contribute to malignant
progression.
Because Pten is a key regulator of the Akt/mTOR pathway, the
Pten status may impact the therapeutic success of mTOR
inhibiting drugs. Previously it was shown that MPNST cell lines
are sensitive to mTOR inhibitors in vitro and in vivo [9,21,22].
The IC50 of the tested mTOR antagonists (rapamycin and
everolimus) was around 10 nM. However, beside NF1 status, the
cell lines used in these studies were not examined for other
molecular alterations that might cause activation of the Akt/
mTOR pathway. We hypothesized that loss of Pten expression
could contribute to activation of this pathway and that patients
with Pten-deficient tumours might particularly profit from
treatment with mTOR inhibitors. In the 5 MPNST cell lines
tested no significant correlation between Pten levels and rapamy-
cin sensitivity was detected.
In contrast to solid MPNST, which generally harbour only few
Pten positive cells (Fig. 1a) most MPNST cell lines maintain Pten
expression although on a lower level compared to Schwann cells
(Fig. 3a and b). A possible explanation for this finding is senescence
induction by complete loss of PTEN expression [24]. Thus, partial
Pten expression may have a selective advantage over a complete
loss at least in the absence of further mutations able to prevent
senescence induction [24].
An impact of Pten status on sensitivity to mTOR inhibitors has
been observed in PTEN-deficient tumour cells and Pten-deficient
MEFs, which were both more sensitive to mTOR inhibitors than
corresponding Pten positive cells [23]. Another study demonstrat-
ed that rapamycin enhanced the sensitivity of Pten-deficient
glioblastoma cells to treatment with the EGFR inhibitor erlotinib
[25]. Moreover, the rapamycin derivate everolimus radiosensitized
Pten-deficient prostate cancer cells more than wildtype cells [26].
Our data could not support a clear correlation of Pten expression
levels and sensitivity to rapamycin. However, since MPNST are
not homogeneous tumours and may harbour different genetic
alterations that might influence the Akt/mTOR pathway further
studies are needed to clarify the impact of Pten status for
therapeutic strategies.
Combination of Drugs
Although mTOR inhibitors show good effects in vitro, in vivo
studies demonstrated their limitation as a single agent. A major
problem of targeted therapy is the capability of cancer cells to use
alternate pathways for survival and proliferation thereby escaping
from specific inhibitors. This problem may be circumvented by
either targeting the driving mutation (if there is one) or by drug
combinations. Here, we tested different combinations of drugs
(Figure S2) and found that the combination of rapamycin and
simvastatin yielded best results. Simvastatin, a 3-hydroxy-3-
methylglutaryl coenzyme A (HMG CoA) reductase inhibitor, is
commonly applied as cholesterol-lowering drug. Anti-tumour
effects of statins have been described [27,28,29]. The anti-
proliferative and pro-apoptotic effects of statins are mediated by
multiple mechanisms including blockage of posttranslational
modification (prenylation) of Ras superfamily members. Statins
have already been shown to improve NF1 symptoms like learning
deficits [30], bone healing [31] and to inhibit proliferation of an
MPNST cell line [32]. However, simvastatin9s exact mode of
action on MPNST cell lines needs further analysis in future
studies.
We and others found only a weak additive effect when mTOR
inhibitors were combined with receptor tyrosine kinase (RTK)
inhibitors (e.g. sunitinib and erlotinib) [21]. Thus, inhibition of
PTEN in MPNST
PLOS ONE | www.plosone.org 6 November 2012 | Volume 7 | Issue 11 | e47595
signalling molecules downstream of RTKs might be more effective
because i) multiple RTKs signal via the same downstream
cascades and ii) these pathways may be constitutively activated
due to mutations in more than one molecule.
Significance of Pten in Neural Tissue
Pten is, like neurofibromin, most strongly expressed in the
central and peripheral nervous system (PNS). However, the exact
cell types expressing Pten in the PNS were not assessed. Here we
show that Pten is strongly expressed in axons and Schwann cells.
Subtle reduction in Pten expression could predispose to tumour-
igenesis in a tissue-specific manner. Neoplasms most commonly
observed in NF1 patients are nerve sheath tumours, which
originate from Schwann cell precursors. It is tempting to speculate
that cell types with strong basal Pten expression are particularly in
danger of undergoing malignant transformation upon Pten loss or
down-regulation. Pten deficiency is frequently observed in primary
glioblastomas but not in astrocytomas grade I-III, underlining its
role in malignant progression [33]. Since the mTOR pathway is
already activated in NF1-associated tumours due to a lack of NF1,
it is likely that further activation of the Akt/mTOR pathway due
to Pten loss promotes tumour progression in this setting. In animal
studies, it was shown that Pten loss altered brain development
[34,35,36] and caused nerve sheath tumour formation [10,37].
Pten Regulation
Regulation of Pten expression is complex and may be caused by
multiple mechanisms including allelic loss, point mutations,
epigenetic silencing, miRs, protein stability (interaction with other
proteins) and ubiquitination [24]. Previously, we found reduced
PTEN gene dosage in more than half of MPNST [7]. Here, we
screened for PTEN mutations, determined promotor methylation,
and the expression of Pten-regulating miRs. Finally, we correlated
these data with Pten transcription and protein levels. We can
exclude, that PTEN mutations play a major role in its regulation or
function. Nevertheless, our previous finding of frequent mono-
allelic loss in MPNST is likely to account for decreased Pten
expression. PTEN haploinsufficiency or even subtle Pten down-
regulation by 20% has been shown to promote tumour
development or progression [38,39]. It was therefore proposed
that loss of Pten may be regarded as a continuum rather than a
stepwise process [24].
Figure 4. Effect of rapamycin on MPNST cell lines and fibroblasts. a) Dose dependent inhibition of proliferation after 4 days of treatment. b)
Pten protein levels correlate with rapamycin sensitivity.
doi:10.1371/journal.pone.0047595.g004
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A gene dosage effect in tumour development is also known from
patients with PTEN harmatoma tumour syndrome, which is
caused by a mono-allelic PTEN germ line mutation. Tumours
from these patients do not always carry PTEN mutations in the
second allele [40].
Moreover, PTEN promotor methylation correlated significantly
with development of metastasis. However, since clinical data was
only available for 21 MPNST and metastasis development is
influenced by many different factors our finding needs to be
confirmed in a larger set of well characterized patients.
A correlation between promotor methylation and transcription
was less clear. A possible explanation may be the small set of
tumours for which both, DNA and RNA, was available.
Moreover, the effect may be masked by other Pten-regulating
mechanisms. Since Pten protein and transcript levels did not
correlate well in all tumours additional posttranscriptional
mechanisms may play a role in Pten regulation. miRs interfere
with transcript translation and have been reported to play an
important role in Pten regulation [41]. We observed an inverse
correlation between miR-21 and Pten protein levels (Fig. 3b & d).
miR-21 is among the most commonly and dramatically upregu-
lated miRs in many cancers and is a well known Pten regulator
[41,42]. Thus, our data point to a possible role of miR-21 in the
regulation of Pten regulation in nerve sheath tumours. However,
this issue needs further evaluation and should include larger panels
of primary tumours. Taken together, our data suggest that a
combination of multiple mechanisms leads to altered Pten
expression in nerve sheath tumours.
In summary, accumulating evidence supports the assumption of
Pten being an important player in MPNST development. Whether
determination of Pten expression status in MPNST might assist in
refining therapy needs further evaluation in clinical studies.
However, we suggest that approaches with mTOR inhibitors in
combination with other agents (e.g. conventional chemotherapy or
statins) could improve therapeutic success.
Supporting Information
Figure S1 Lack of Nf1 does not alter Pten expression but
activates the Ras/MAPK and mTOR pathway. a) MEFs of the
indicated genotype were kept under different conditions and
analysed by western blot. The boxes mark culture conditions,
where differences between the two genotypes are most pro-
nounced. b) The assay was repeated with slightly different culture
conditions. The significance of Nf1 status for mTOR activation
was determined as the ration between p-mTOR to total mTOR.
All samples were tested in duplicates.
(TIF)
Figure S2 Anti-proliferative effect of different drugs on MPNST
cell lines and fibroblasts. a) simvastatin, rapamycin and the
combination of both drugs b) rapamycin, sunitinib and the
combination of both drugs c) simvastatin, sunitinib and the
combination of both drugs
(TIF)
Figure S3 Kaplan-Meier curve shows metastasis free time in
patients with promotor methylation,29% and $29%.
(TIF)
Figure S4 Nuclear Pten localization in MPNST and neurofi-
broma was determined by immunohistochemistry. Each dot
represents one tumour. The difference of nuclear Pten in MPNST
and neurofibroma was not significant (p = 0.1, unpaired t-test).
(TIF)




We thank P. Matylewski, C. Gelhaar, and S. Korge for excellent technical
assistance, D. Kaufmann for providing the MEFs, and C. Mawrin for
MPNST slides.
Author Contributions
Conceived and designed the experiments: NH CH FH M. Bradtmöller
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